Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$27000.0.

  • Phathom Pharmaceuticals' Cash from Investing Activities rose 3863.64% to -$27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$147000.0, marking a year-over-year increase of 7570.25%. This contributed to the annual value of -$135000.0 for FY2024, which is 9173.81% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Cash from Investing Activities of -$27000.0 as of Q3 2025, which was up 3863.64% from -$97000.0 recorded in Q2 2025.
  • Phathom Pharmaceuticals' Cash from Investing Activities' 5-year high stood at -$5000.0 during Q4 2024, with a 5-year trough of -$939000.0 in Q3 2023.
  • For the 4-year period, Phathom Pharmaceuticals' Cash from Investing Activities averaged around -$196800.0, with its median value being -$67000.0 (2022).
  • Within the past 5 years, the most significant YoY rise in Phathom Pharmaceuticals' Cash from Investing Activities was 9894.74% (2024), while the steepest drop was 66666.67% (2024).
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Cash from Investing Activities stood at -$412000.0 in 2022, then dropped by 15.29% to -$475000.0 in 2023, then surged by 98.95% to -$5000.0 in 2024, then tumbled by 440.0% to -$27000.0 in 2025.
  • Its Cash from Investing Activities was -$27000.0 in Q3 2025, compared to -$97000.0 in Q2 2025 and -$18000.0 in Q1 2025.